北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科  > 期刊论文
学科主题: 临床医学
题名:
Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials
作者: Lee, Chongyou; Geng, Qiang; Ren, Jingyi; Chen, Hong; Liang, Wenqing
关键词: adverse events ; fenofibrate ; meta-analysis ; statin
刊名: CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
发表日期: 2013-03-01
DOI: 10.1111/1440-1681.12053
卷: 40, 期:3, 页:219-226
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy ; Physiology
研究领域[WOS]: Pharmacology & Pharmacy ; Physiology
关键词[WOS]: TYPE-2 DIABETES-MELLITUS ; COMBINED HYPERLIPIDEMIA ; DOUBLE-BLIND ; COMBINATION THERAPY ; PLUS FENOFIBRATE ; LIPID THERAPY ; DYSLIPIDEMIA ; SIMVASTATIN ; ATORVASTATIN ; TOLERABILITY
英文摘要:

The combination of fenofibrate with statins is a beneficial therapeutic option for patients with mixed dyslipidaemia, but concerns about adverse events (AEs) make physicians reluctant to use this combination therapy. Medline, Embase and the Cochrane Library were searched to identify 13 randomized controlled trials, involving 7712 patients, of statinfenofibrate therapy versus statin alone for review. There were significant decreases in low-density lipoproteincholesterol, triglycerides and total cholesterol and increases in high-density lipoproteincholesterol in patients receiving combination therapy compared with statin therapy alone. The incidence of aminotransferase elevations in the fenofibratestatin therapy group was significantly higher than in the statin monotherapy group (odds ratio (OR), 1.66; 95% confidence interval (CI) 1.172.37; P<0.05). The incidence of elevated creatine kinase levels (OR 0.88; 95% CI 0.631.23; 0.05), muscle-associated AEs (OR 0.98; 95% CI 0.881.09; 0.05) and withdrawals attributed to liver and muscle dysfunction did not differ significantly between the two groups. The efficacy of fenofibrate+standard-dose statin and incidence of AEs in the fenofibrate+standard-dose statin group were almost identical to those in the fenofibratestatin group. In conclusion, combination therapy improves the blood lipid profile of patients. Fenofibratestatin combination therapy appears to be as well tolerated as statin monotherapy. Physicians should consider fenofibratestatin combination therapy in patients but monitor aminotransferase levels to avoid hepatic complications.

语种: 英语
所属项目编号: NSFC 30570712
项目资助者: National Natural Science Foundation of China
WOS记录号: WOS:000315447000008
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50287
Appears in Collections:北京大学第二临床医学院_心血管内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Dept Cardiol, Peoples Hosp, Beijing 100044, Peoples R China

Recommended Citation:
Lee, Chongyou,Geng, Qiang,Ren, Jingyi,et al. Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials[J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,2013,40(3):219-226.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Lee, Chongyou]'s Articles
[Geng, Qiang]'s Articles
[Ren, Jingyi]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Lee, Chongyou]‘s Articles
[Geng, Qiang]‘s Articles
[Ren, Jingyi]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace